- Home
- EML vs CHRS Comparison
EML vs CHRS Comparison
Compare EML & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- CHRS
- Stock Information
- Founded
- EML 1858
- CHRS 2010
- Country
- EML United States
- CHRS United States
- Employees
- EML N/A
- CHRS N/A
- Industry
- EML Industrial Machinery/Components
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EML Consumer Discretionary
- CHRS Health Care
- Exchange
- EML Nasdaq
- CHRS Nasdaq
- Market Cap
- EML 144.5M
- CHRS 84.2M
- IPO Year
- EML N/A
- CHRS 2014
- Fundamental
- Price
- EML $22.75
- CHRS $0.88
- Analyst Decision
- EML
- CHRS Buy
- Analyst Count
- EML 0
- CHRS 3
- Target Price
- EML N/A
- CHRS $4.68
- AVG Volume (30 Days)
- EML 14.0K
- CHRS 1.3M
- Earning Date
- EML 08-05-2025
- CHRS 08-07-2025
- Dividend Yield
- EML 1.93%
- CHRS N/A
- EPS Growth
- EML N/A
- CHRS N/A
- EPS
- EML N/A
- CHRS N/A
- Revenue
- EML $271,440,503.00
- CHRS $272,251,000.00
- Revenue This Year
- EML $1.56
- CHRS N/A
- Revenue Next Year
- EML $7.00
- CHRS $99.43
- P/E Ratio
- EML $11.01
- CHRS N/A
- Revenue Growth
- EML 8.15
- CHRS 19.87
- 52 Week Low
- EML $19.06
- CHRS $0.66
- 52 Week High
- EML $35.03
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- EML 42.29
- CHRS 55.66
- Support Level
- EML $24.04
- CHRS $0.82
- Resistance Level
- EML $24.57
- CHRS $0.94
- Average True Range (ATR)
- EML 0.65
- CHRS 0.06
- MACD
- EML -0.12
- CHRS 0.01
- Stochastic Oscillator
- EML 33.22
- CHRS 67.00
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.